MannkindLogoStackedPreferd.jpg
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
18. September 2024 06:15 ET | MannKind CLEAR® Verified
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment
MannkindLogoStackedPreferd.jpg
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
10. September 2024 16:30 ET | MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...
MannkindLogoStackedPreferd.jpg
MannKind to Present at Upcoming Conferences
27. August 2024 16:30 ET | MannKind
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...
MannkindLogoStackedPreferd.jpg
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
14. August 2024 08:00 ET | MannKind
KENT KRESA TO RETIRE FROM MANNKIND’S BOARD OF DIRECTORS; STEVEN B. BINDER TO BE APPOINTED TO THE BOARD
MannkindLogoStackedPreferd.jpg
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
07. August 2024 08:00 ET | MannKind
2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total revenues of $139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of $29 millionAdvances two orphan lung...
MannkindLogoStackedPreferd.jpg
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
31. Juli 2024 06:30 ET | MannKind
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
MannkindLogoStackedPreferd.jpg
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
30. Juli 2024 16:30 ET | MannKind
MANNKIND CORPORATION TO HOLD 2024 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 7, 2024
Afrezza (inhaled insulin) in use
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
22. Juni 2024 08:00 ET | MannKind
INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED
MannkindLogoStackedPreferd.jpg
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
05. Juni 2024 06:45 ET | MannKind
INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION’S 84TH SCIENTIFIC SESSIONS
MannkindLogoStackedPreferd.jpg
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
29. Mai 2024 08:45 ET | MannKind
MANNKIND TO ESTABLISH BOSTON-AREA RESEARCH & DEVELOPMENT FOOTHOLD AND EXPAND PORTFOLIO OF DRY POWDER INHALATION TECHNOLOGY IN TRANSACTION WITH PULMATRIX